Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. reports news on its medical supplies business, centered on insulin delivery products and diabetes-care devices. The company sells pen needles, syringes and safety devices through wholesalers, distributors and institutional channels, and it has described a transition from insulin delivery toward a broader medical supplies platform.
Recurring updates include quarterly operating and financial results, cash dividend declarations, conference participation, board leadership changes, operational updates, capital-structure matters, material agreements, and regulatory or clinical disclosures tied to its device portfolio and manufacturing activities.
embecta (Nasdaq: EMBC) announced management will participate in several June 2026 healthcare investor events in the U.S.
These include conferences hosted by Jefferies, TD Cowen, Goldman Sachs, and Truist Securities, featuring one-on-one investor meetings and a fireside session across New York, New Orleans, Miami, and Boston.
embecta (Nasdaq: EMBC) has completed its acquisition of Owen Mumford Holdings, a UK-based medical device and drug delivery innovator. The deal includes a £100 million upfront cash payment and up to £50 million in performance-based payments tied to Aidaptus® auto-injector net sales.
The transaction is intended to accelerate embecta’s shift into a broad medical supplies and drug delivery platforms business, expanding its chronic care product portfolio, intellectual property, manufacturing capabilities, and global commercial reach across obesity, diabetes, autoimmune diseases and anaphylaxis markets.
Embecta (Nasdaq: EMBC) will present at the 2026 BofA Securities Global Health Care Conference in Las Vegas on May 13, 2026 at 3:00 p.m. PT / 6:00 p.m. ET. Audio webcasts will be available via the News & Events section of the company's investor relations site at investors.embecta.com.
embecta (Nasdaq: EMBC) declared a quarterly cash dividend of $0.01 per share. The dividend is payable on June 15, 2026 to shareholders of record at the close of business on May 28, 2026.
Embecta (Nasdaq: EMBC) reported second quarter fiscal 2026 financial results and announced an analyst and investor conference call and live webcast on May 5, 2026 at 8:00 a.m. ET. A webcast replay will be available beginning at 11:00 a.m. ET on May 5, 2026 and archived for one year on the investor website.
Investors are directed to the company investor relations site for the full earnings press release and presentation.
embecta (Nasdaq: EMBC) will report fiscal second quarter 2026 results and host a live conference call and webcast on May 5, 2026 at 8:00 a.m. ET. A replay will be available beginning at 11:00 a.m. ET on the embecta investor relations website and archived for one year.
embecta (Nasdaq: EMBC) agreed to acquire UK-based Owen Mumford for up to £150 million—£100 million upfront plus up to £50 million in performance payments tied to Aidaptus® sales over three years. The deal is expected to close in embecta’s fiscal Q3 2026, subject to approvals.
The acquisition adds drug-delivery platforms, a £69.4M FY2025 revenue base, manufacturing capabilities and global commercial reach to accelerate embecta’s transformation into a broad-based medical supplies company.
embecta (Nasdaq: EMBC) announced board leadership changes effective February 11, 2026: Devdatt "Dev" Kurdikar was elected Chairman of the Board and Dr. Claire Pomeroy was elected Lead Independent Director. These changes follow the retirement of LTG (Ret.) David F. Melcher.
Kurdikar joins as chairman after serving as president and CEO of a diabetes care spinoff since 2022. Dr. Pomeroy will continue to chair the Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee.
Embecta (Nasdaq: EMBC) reported first quarter fiscal 2026 financial results on February 5, 2026. The company directs investors to its Investor Relations website for the detailed earnings release and presentation.
Embecta hosted a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET on February 5, 2026, with a replay available beginning at 11:00 a.m. ET on February 5, 2026 and archived for one year on the investor relations site.
embecta (Nasdaq: EMBC) declared a quarterly cash dividend of $0.15 per share. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. This applies to all issued and outstanding common shares.